PDF herunterladen
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2021; 42(03): 301-304
DOI: 10.1055/s-0041-1732860
Case Report with Review of Literature

Transient Abnormal Myelopoiesis with a Novel GATA1 Mutation in a Child with Down Syndrome: A Case Report and Brief Review

Mohanaraj Ramachandran
1   Department of Pediatrics, Division of Pediatric Oncology, All India Institute of Medical Sciences, New Delhi, India
,
Prasanth Srinivasan
1   Department of Pediatrics, Division of Pediatric Oncology, All India Institute of Medical Sciences, New Delhi, India
,
Jagdish Prasad Meena
1   Department of Pediatrics, Division of Pediatric Oncology, All India Institute of Medical Sciences, New Delhi, India
,
Aditya Kumar Gupta
1   Department of Pediatrics, Division of Pediatric Oncology, All India Institute of Medical Sciences, New Delhi, India
,
Tanya Prasad
2   Laboratory Oncology Unit, Dr. B. R. A. IRCH, All India Institute of Medical Sciences, New Delhi, India
,
Rachna Seth
1   Department of Pediatrics, Division of Pediatric Oncology, All India Institute of Medical Sciences, New Delhi, India
› Institutsangaben Funding None
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Transient abnormal myelopoiesis (TAM) is a unique entity seen in children with Down syndrome (DS) with 10 to 20% risk of developing myeloid leukemia in the first 5 years of life. We report a 2 months old male infant with DS detected to have hyperleukocytosis on routine preoperative workup for cyanotic congenital heart disease. Peripheral blood and bone marrow aspiration showed blasts, and next-generation sequencing detected a novel GATA1 mutation, and a diagnosis of TAM was confirmed in this child. This mutation has not been reported in TAM in the literature earlier to the best of our knowledge.

Keywords

transient abnormal myelopoiesis - Down syndrome - GATA1 mutation - hyperleukocytosis


Publikationsverlauf

Artikel online veröffentlicht:
20. September 2021

© 2021. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down’s syndrome. Lancet 2000; 355 (9199) 165-169
    CrossrefPubMedGoogle Scholar
  • 2 Patja K, Pukkala E, Sund R, Iivanainen M, Kaski M. Cancer incidence of persons with Down syndrome in Finland: a population-based study. Int J Cancer 2006; 118 (07) 1769-1772
    CrossrefPubMedGoogle Scholar
  • 3 Malinge S, Izraeli S, Crispino JD. Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome. Blood 2009; 113 (12) 2619-2628
    CrossrefPubMedGoogle Scholar
  • 4 Roberts I, Izraeli S. Haematopoietic development and leukaemia in Down syndrome. Br J Haematol 2014; 167 (05) 587-599
    CrossrefPubMedGoogle Scholar
  • 5 Roberts I, Alford K, Hall G. et al Oxford-Imperial Down Syndrome Cohort Study Group. GATA1-mutant clones are frequent and often unsuspected in babies with Down syndrome: identification of a population at risk of leukemia. Blood 2013; 122 (24) 3908-3917
    CrossrefPubMedGoogle Scholar
  • 6 Yoshida K, Toki T, Okuno Y. et al The landscape of somatic mutations in Down syndrome-related myeloid disorders. Nat Genet 2013; 45 (11) 1293-1299
    CrossrefPubMedGoogle Scholar
  • 7 Tunstall O, Bhatnagar N, James B. et al British Society for Haematology. Guidelines for the investigation and management of transient leukaemia of Down syndrome. Br J Haematol 2018; 182 (02) 200-211
    CrossrefPubMedGoogle Scholar
  • 8 Bhatnagar N, Nizery L, Tunstall O, Vyas P, Roberts I. Transient abnormal myelopoiesis and AML in Down syndrome: an update. Curr Hematol Malig Rep 2016; 11 (05) 333-341
    CrossrefPubMedGoogle Scholar
  • 9 Homans AC, Verissimo AM, Vlacha V. Transient abnormal myelopoiesis of infancy associated with trisomy 21. Am J Pediatr Hematol Oncol 1993; 15 (04) 392-399
    Google Scholar
  • 10 Cantor AB. GATA transcription factors in hematologic disease. Int J Hematol 2005; 81 (05) 378-384
    CrossrefPubMedGoogle Scholar
  • Miyauchi J. Unique Myeloid Leukemias in Young Children with Down Syndrome: Cell Origin, Association with Hematopoietic Microenvironment and Leukemogenesis. Prenat Diagn Screen Syndr [Internet]. 2011 Aug 17 [cited 2020 Dec 19]; Available from: https://www.intechopen.com/books/prenatal-diagnosis-and-screening-for-down-syndrome/unique-myeloid-leukemias-in-young-children-with-down-syndrome-cell-origin-association-with-hematopoi. Accessed July 5, 2021
  • 12 Ciovacco WA, Raskind WH, Kacena MA. Human phenotypes associated with GATA-1 mutations. Gene 2008; 427 (1-2) 1-6
    CrossrefPubMedGoogle Scholar
  • 13 Alford KA, Reinhardt K, Garnett C. et al International Myeloid Leukemia-Down Syndrome Study Group. Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia. Blood 2011; 118 (08) 2222-2238
    CrossrefPubMedGoogle Scholar
  • 14 Singh A, Mandal A, Guru V, Srinivasan S, Seth R. Transient abnormal myelopoiesis: a varied spectrum of clinical presentation. J Hematol (Brossard 2017; 6 (01) 25-28
    CrossrefPubMedGoogle Scholar
  • 15 Muramatsu H, Watanabe T, Hasegawa D. et al Prospective study of 168 infants with transient abnormal myelopoiesis with Down syndrome: Japan Pediatric Leukemia/Lymphoma Study Group, TAM-10 Study. Blood 2015; 126 (23) 1311
    CrossrefGoogle Scholar